TP53 and breast carcinoma: Alternatively, based on the insight that extended cell cycle arrest at the G2 phase would switch the p53-mediated cell cycle response from pro-survival to pro-apoptosis, our group developed a coordination nanoassembly of ferrous ions and DNAzymes for the targeted degradation of F-box and WD repeat domain containing 7 (FBXW7) mRNA in breast cancer cells, which is an upstream negative regulator of phosphorylated p53 (Figure 5D-E) 137.